What is the official website of Hikma Pharmaceuticals ?

The official website of Hikma Pharmaceuticals is http://www.hikma.com.

What is Hikma Pharmaceuticals's cybersecurity risk score?

Hikma Pharmaceuticals has an AI-generated cybersecurity risk score of 767 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Hikma Pharmaceuticals experienced?

According to Rankiteo, Hikma Pharmaceuticals currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Hikma Pharmaceuticals been affected by any supply chain cyber incidents ?

According to Rankiteo, Hikma Pharmaceuticals has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Hikma Pharmaceuticals have SOC 2 Type 1 certification ?

According to Rankiteo, Hikma Pharmaceuticals is not certified under SOC 2 Type 1.

Does Hikma Pharmaceuticals have SOC 2 Type 2 certification ?

According to Rankiteo, Hikma Pharmaceuticals does not hold a SOC 2 Type 2 certification.

Does Hikma Pharmaceuticals comply with GDPR ?

According to Rankiteo, Hikma Pharmaceuticals is not listed as GDPR compliant.

Does Hikma Pharmaceuticals have PCI DSS certification ?

According to Rankiteo, Hikma Pharmaceuticals does not currently maintain PCI DSS compliance.

Does Hikma Pharmaceuticals comply with HIPAA ?

According to Rankiteo, Hikma Pharmaceuticals is not compliant with HIPAA regulations.

Does Hikma Pharmaceuticals have ISO 27001 certification ?

According to Rankiteo,Hikma Pharmaceuticals is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Hikma Pharmaceuticals operate in ?

Hikma Pharmaceuticals operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Hikma Pharmaceuticals have ?

Hikma Pharmaceuticals employs approximately 10,252 people worldwide.

Does Hikma Pharmaceuticals own any subsidiaries ?

Hikma Pharmaceuticals presently has no subsidiaries across any sectors.

How many LinkedIn followers does Hikma Pharmaceuticals have ?

Hikma Pharmaceuticals's official LinkedIn profile has approximately 637,630 followers.

What is the NAICS classification code for Hikma Pharmaceuticals ?

Hikma Pharmaceuticals is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Hikma Pharmaceuticals have a Crunchbase profile ?

Yes, Hikma Pharmaceuticals has an official profile on Crunchbase, which can be accessed here: https://www.crunchbase.com/organization/hikma-pharmaceuticals.

Does Hikma Pharmaceuticals have a LinkedIn profile ?

Yes, Hikma Pharmaceuticals maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/hikma-pharmaceuticals.

How many cybersecurity incidents has Hikma Pharmaceuticals experienced ?

As of August 9, 2026, Rankiteo reports that Hikma Pharmaceuticals has not experienced any cybersecurity incidents.

How many peer or competitor companies does Hikma Pharmaceuticals have ?

Hikma Pharmaceuticals has an estimated 5,727 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Hikma Pharmaceuticals

Boost Score +25 with badge (5 left)

767

/1000

Fair

792

/1000

Fair

Hikma Pharmaceuticals Vendor Cyber Rating & Cyber Score

hikma.com

cb in

Add Your Compliance Badge

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

Hikma Pharmaceuticals A.I CyberSecurity Scoring

Scoring History

Hikma Pharmaceuticals

Hikma Pharmaceuticals CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Hikma Pharmaceuticals Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Hikma Pharmaceuticals

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Hikma Pharmaceuticals in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Hikma Pharmaceuticals in 2026.

Incident Types Hikma Pharmaceuticals vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Hikma Pharmaceuticals in 2026.

Incident History - Hikma Pharmaceuticals (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Hikma Pharmaceuticals Subsidiaries

Parent Company

Hikma Pharmaceuticals

Pharmaceutical Manufacturing

Website: http://www.hikma.com

Company Size: 5,001-10,000 employees

No subsidiary data available for this company.

Loading…

Hikma Pharmaceuticals Similar Companies

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

Sanofi

sanofi.com

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

Alembic Pharmaceuticals Limited

alembic-india.com

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

Merck Group

merckgroup.com

This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trademark MERCK in the U.S. and Canada. _______________________________ We are Merck, a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Work your Magic and join Merck. Legal Disclaimer: www.merckgroup.com/en/legal-disclaimer.html Data Privacy Declaration: www.merckgroup.com/en/privacy-statement

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

Alkem Laboratories Ltd.

alkemlabs.com

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’.

Fresenius Kabi

fresenius-kabi.com

As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With over 41,000 employees and present in over 100 countries, Fresenius Kabi’s expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients’ nutritional status. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is the global leader in supplying blood collection bags and devices, supporting blood banks and healthcare facilities worldwide. The company’s I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care. Fresenius Kabi takes a holistic approach to healthcare and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. With the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of healthcare. Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing healthcare solutions on a global scale. User information & community guidelines: https://www.fresenius-kabi.com/social-media-terms-conditions Imprint: www.fresenius-kabi.com/imprint

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Loading…

NEWS

Hikma Pharmaceuticals CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

March 05, 2026 08:00 AM

How The Hikma Pharmaceuticals (LSE:HIK) Investment Story Is Shifting As Analyst Views Diverge

Hikma Pharmaceuticals is back in focus after its fair value estimate was trimmed from £21.82 to £20.47. This shift has put fresh attention...

Read Article

February 26, 2026 08:00 AM

Hikma Pharma's gloomy outlook kicks shares to more than three-year low

British generic drugmaker Hikma Pharmaceuticals scrapped its medium-term targets as it forecast slower annual revenue growth and profit on...

Read Article

February 06, 2026 08:00 AM

What Analysts Think Is Changing The Story For Hikma Pharmaceuticals (LSE:HIK)

The latest update on Hikma Pharmaceuticals focuses on the price target, with the modelled fair value held at 22.14 while core assumptions...

Read Article

January 08, 2026 08:00 AM

Looking At The Narrative For Hikma Pharmaceuticals LSE HIK After Analyst Split On Fair Value

Hikma Pharmaceuticals' fair value estimate has been nudged down from £22.66 to £22.00 per share, a small adjustment that better reflects the...

Read Article

December 16, 2025 08:00 AM

The Character of the Corporation 2025: Navigating Tumultuous Times for Multinational Businesses

Directors Nina Henderson and John Zangardi on the key differences between serving on multinational and domestic boards.

Read Article

December 15, 2025 08:00 AM

How the Narrative Around Hikma Pharmaceuticals Is Shifting After Recent Analyst Target Moves

Hikma Pharmaceuticals' latest valuation update points to a slightly lower fair value estimate of about $22.66 per share, even as analysts...

Read Article

November 28, 2025 08:00 AM

How Recent Developments Are Shaping the Hikma Pharmaceuticals Story and Its Valuation

Hikma Pharmaceuticals' consensus analyst price target has seen a slight dip, moving from £23.55 to £23.36 per share.

Read Article

November 13, 2025 08:00 AM

Why The Narrative Around Hikma Pharmaceuticals Is Shifting After Recent Analyst Updates

Hikma Pharmaceuticals has recently seen its fair value estimate reduced from £25.40 to £23.55, as analysts update their assessments in light...

Read Article

September 19, 2025 07:00 AM

Hikma Pharmaceuticals PLC (LON:HIK) is favoured by institutional owners who hold 59% of the company

Key Insights Institutions' substantial holdings in Hikma Pharmaceuticals implies that they have significant influence...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-71983

SUMMARY

MSI Radix AXE6600 router firmware version v781521 contains a command injection vulnerability in the wps.cgi interface that allows remote attackers to execute arbitrary commands by injecting malicious input through the pin2g, pin5g, or pin6g parameters. Attackers can exploit these unsanitized parameters to execute arbitrary commands on the affected device and obtain root privileges.

Published

Date2026-08-08

Updated

Date2026-08-08

RISK INFORMATION (Score: 9.8)

cvss3

Base Score: 9.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

3.9

REFERENCES

CVE-2026-71502

SUMMARY

CTI-Transmute contains a stored cross-site scripting vulnerability caused by insufficient neutralization of Vue template expression delimiters in server-rendered user-controlled data. An unauthenticated attacker can create a public conversion whose name or description contains a malicious Vue expression using the application's configured [[ ... ]] delimiters. User profile names may provide an additional injection vector. Although Jinja HTML escaping is applied, the resulting value is subsequently included in a DOM region compiled by Vue. Vue interprets the attacker-controlled value as a template expression rather than ordinary text. By accessing the JavaScript Function constructor from within the expression, an attacker can execute arbitrary JavaScript in the security context of the CTI-Transmute origin. The application's nonce-based Content Security Policy does not prevent exploitation because the Vue runtime compiler requires the unsafe-eval policy exception. The malicious payload is stored by the application and executed whenever another user opens an affected page, such as the public conversion detail page. The victim may be a normal user or an administrator. Successful exploitation could allow the attacker to: * Access data available to the victim through the application. * Extract API keys, tokens, or other sensitive information exposed to the page. * Perform authenticated actions using the victim's session. * Modify conversions or other application data. * Escalate the impact by targeting an administrator. A demonstrated payload can use [].constructor.constructor(...) to obtain the JavaScript Function constructor and execute arbitrary code. The regression tests also show that a short first-stage payload could retrieve an uncapped conversion description and evaluate a larger second-stage payload. The patch addresses the vulnerability by registering a global Jinja finalize hook that inserts a zero-width Unicode word joiner inside every Vue delimiter found in server-rendered values. This prevents Vue from recognizing the values as template expressions while preserving their visible representation.

Published

Date2026-08-08

Updated

Date2026-08-08

RISK INFORMATION (Score: )

cvss4

Base Score: 5.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:A/VC:L/VI:L/VA:N/SC:L/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-71958

SUMMARY

D-Link DWR-M961 devices with hardware version C1 and software version 1.1.2_C1_202602110044 contain a buffer overflow vulnerability in the quicksetup.cgi interface. A remote attacker can write overly long strings to the test4, ssid2, and username fields and execute arbitrary commands by crafting a specific payload, or cause the device to crash.

Published

Date2026-08-08

Updated

Date2026-08-08

RISK INFORMATION (Score: 9.8)

cvss3

Base Score: 9.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

3.9

REFERENCES

CVE-2026-71957

SUMMARY

D-Link DWR-M961 devices with hardware version C1 and software version 1.1.2_C1_202602110044 contain a buffer overflow vulnerability in the app.cgi interface. A remote attacker can write an overly long string to the netAcc.addlist[].name field and execute arbitrary commands by crafting a specific payload, or cause the device to crash.

Published

Date2026-08-08

Updated

Date2026-08-08

RISK INFORMATION (Score: 9.8)

cvss3

Base Score: 9.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

3.9

REFERENCES

CVE-2026-71956

SUMMARY

D-Link DWR-M961 devices with hardware version C1 and software version 1.1.2_C1_202602110044 contain a command injection vulnerability in the app.cgi interface. A remote attacker can inject arbitrary malicious commands into the netDig.ping.dst field, resulting in command execution with root privileges.

Published

Date2026-08-08

Updated

Date2026-08-08

RISK INFORMATION (Score: 9.8)

cvss3

Base Score: 9.8

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H

cvss4

Base Score: 9.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

3.9

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…